Key Highlights
- Shares rose 3.37% in pre-market trading to $11.95, up from a prior close of $11.56
- FDA granted Breakthrough Device Designation to SimpleScreen Lung, the company's investigational blood-based lung cancer screening test
- Test is designed for adults ages 50 to 80 with a 20 pack-year smoking history who are not currently participating in guideline-recommended screening
- Only about 18% of eligible U.S. adults currently receive recommended lung cancer screening
- 52-week range stands at $9.95 to $14.47, with a market Capitalization of $94.30 million
Shares Rise on Breakthrough Device Designation
Freenome (NASDAQ:FRNM) shares rose 3.37% in pre-market trading to $11.95, up from a prior close of $11.56, after the U.S. Food and Drug Administration granted Breakthrough Device Designation to SimpleScreen Lung, the company's investigational blood-based lung cancer screening test. The designation applies to the proposed use of the test in adults ages 50 to 80 with at least a 20 pack-year smoking history who are not currently participating in guideline-recommended lung cancer screening.
The Breakthrough Devices Program is designed to accelerate development and review of medical devices addressing life-threatening or irreversibly debilitating diseases, offering Freenome the opportunity for interactive communication with the FDA and prioritized review during the premarket submission process. Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of adults for whom screening is recommended have actually been screened, with barriers including strict eligibility criteria for low-dose CT scans, lack of awareness, and concerns about repetitive radiation exposure.
What Freenome Does
Freenome is a South San Francisco, California based early cancer detection company developing blood-based screening tests to identify cancer at its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's SimpleScreen CRC colorectal cancer screening test received FDA approval last month, and the company is now advancing a pipeline of additional tests, including SimpleScreen Lung.
SimpleScreen Lung Builds on Approved Colorectal Cancer Test
SimpleScreen Lung incorporates multiomics through methylation and proteomics technologies with an artificial intelligence and Machine Learning powered classifier to determine whether a lung cancer signal has been detected from a standard blood draw. A positive result would indicate a signal suggesting possible lung cancer that should be followed by low-dose CT imaging, while a negative result would not detect a lung cancer associated signal but would not guarantee the absence of the disease. The company is continuing clinical evaluation of the test through its prospective PROACT LUNG study.
Looking Ahead
Freenome's pre-market gain reflects genuine regulatory progress for a second product in its cancer screening pipeline, building on the recent approval of its colorectal cancer test. With SimpleScreen Lung now benefiting from prioritized FDA review and a substantial addressable population of underscreened high-risk adults, the company's ability to advance the test through the remainder of its clinical evaluation will be the next milestone for investors to watch.


_11_17_2026_13_39_08_971706.jpg)



Please wait processing your request...